Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
505,000
+1,000 (0.20%)
Apr 10, 2026, 3:30 PM KST
Sam Chun Dang Pharm. Revenue
In the year 2025, Sam Chun Dang Pharm. had annual revenue of 231.81B KRW with 9.90% growth. Sam Chun Dang Pharm. had revenue of 66.26B in the quarter ending December 31, 2025, with 20.05% growth.
Revenue
231.81B
Revenue Growth
+9.90%
P/S Ratio
50.67
Revenue / Employee
549.30M
Employees
422
Market Cap
11.75T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 231.81B | 20.88B | 9.90% |
| Dec 31, 2024 | 210.92B | 18.26B | 9.47% |
| Dec 31, 2023 | 192.67B | 15.33B | 8.65% |
| Dec 31, 2022 | 177.34B | 10.06B | 6.01% |
| Dec 31, 2021 | 167.27B | 412.57M | 0.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 3.02T |
| Yuhan | 2.19T |
| Hanmi Pharm. | 1.55T |
| SK Biopharmaceuticals | 706.74B |
| ALTEOGEN | 215.86B |
| LigaChem Biosciences | 141.55B |